C. Saura

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy
202415 citationsauthor #10
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
202315 citationsauthor #9
O-277 Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis
20230 citationsauthor #9
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
2023120 citationsauthor #7
Abstract PD17-07: Cell-Cycle Inhibition and Immune Microenvironment in HR+/HER2- Breast Cancer During and After preoperative ribociclib and letrozole vesus chemotherapy: A correlative analysis of the 1402-SOLTI/CORALLEEN phase 2 trial
20231 citationsauthor #6
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
20239 citationsauthor #49
The impact of Covid-19 pandemic on breast cancer multidisciplinary management at the Vall d'Hebron University Hospital.
20230 citationsauthor #12
The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
202312 citationsauthor #2
Influence of age, sex and tumor type in the likelihood of inclusion in early clinical trials.
20230 citationsauthor #13
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
202327 citationsauthor #23
Abstract GS4-09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13)
202311 citationsauthor #8
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
202349 citationsauthor #24
Abstract PD8-02: Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study
20236 citationsauthor #7
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.
202312 citationsauthor #28
Abstract P4-01-15: Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)
20234 citationsauthor #6
Abstract PD18-10: Treatment of HER2-positive (HER2+) hormone-receptor positive (HR+) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant
20233 citationsauthor #16
RAGE/SNAIL1 signaling drives epithelial-mesenchymal plasticity in metastatic triple-negative breast cancer
20233 citationsauthor #15
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer
20232 citationsauthor #9
Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study
20237 citationsauthor #7
An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.
202311 citationsauthor #8
SA 5.3 What’s next? Antibody-drug conjugates for breast cancer therapy
20230 citationsauthor #2
Early-Stage Breast Cancer Detection in Breast Milk
202334 citationsauthor #1
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).
202339 citationsauthor #16
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
202341 citationsauthor #24
Abstract OT2-10-04: Treatment of advanced or metastatic triple-negative breast cancer with adoptive therapy of PD1+ tumor-infiltrating lymphocytes (TILS001 trial)
20231 citationsauthor #3
Abstract P1-05-14: ctDNA IN BREAST MILK FOR EARLY DETECTION OF PREGNANCY ASSOCIATED BREAST CANCER
20230 citationsauthor #1
Shedding of ctDNA, radiomics assessment of tumor disease volume (TDV), and concordance of mutations (mut) in synchronous liquid and tumor biopsies in metastatic breast cancer (MBC).
20220 citationsauthor #17
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
202261 citationsauthor #10
Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
202222 citationsauthor #4
Abstract P5-17-05: A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer
20223 citationsauthor #6
Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial
20220 citationsauthor #24
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
20221,619 citationsauthor #28
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
20225 citationsauthor #21
Abstract OT1-14-02: Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
20220 citationsauthor #6
Representation of young adult(19–29 y) and elderly(>75 y) patients populations in an early drug development unit
20220 citationsauthor #16
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
202211 citationsauthor #13
Gene expression profile at week 2 of neoadjuvant therapy course predicts outcome in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO
20220 citationsauthor #10
Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC)
20220 citationsauthor #16
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
202266 citationsauthor #9
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
202230 citationsauthor #10
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
20227 citationsauthor #6
Abstract OT2-06-01: Solti-1903 HOPE: Real-world clinical practice study to assess the impact of using genomic data on the next treatment decision making-choice in patients with locally advanced or metastatic breast cancer in Spain
20220 citationsauthor #4
Abstract OT1-12-01: Solti-1804 HER2-PREDICT: Translational study of tumor samples from breast cancer patients treated with trastuzumab deruxtecan in the metastatic setting
20220 citationsauthor #2
92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8
202211 citationsauthor #5
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
20220 citationsauthor #21
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
202268 citationsauthor #36
Epithelial-Mesenchymal plasticity mediates acquired resistance to eribulin in breast cancer
20220 citationsauthor #3
Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial.
20220 citationsauthor #15
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
202234 citationsauthor #28
The conundrum of breast cancer and microbiome - A comprehensive review of the current evidence.
202232 citationsauthor #6
Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)
20220 citationsauthor #2
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
20226 citationsauthor #21
Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer
20225 citationsauthor #12
Identification of homologous recombination deficiency (HRD) by RAD51 in a tumor molecular profiling program for precision medicine.
20221 citationsauthor #16
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
202272 citationsauthor #10
87P EPClin vs OncotypeDx in invasive lobular cancer (ILC)
20220 citationsauthor #18
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
20222 citationsauthor #37
A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort
202211 citationsauthor #7
GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells
202216 citationsauthor #9
Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis
20228 citationsauthor #10
Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).
20228 citationsauthor #11
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.
20226 citationsauthor #15
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
202230 citationsauthor #17
Transition to the new EU CTIS Portal for Regulatory Clinical Trial Submissions: VHIO’s Start-Up Unit Analysis
20220 citationsauthor #13
Abstract PS5-03: Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial
20212 citationsauthor #11
High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
202114 citationsauthor #22
Abstract P069: GDF15 contributes to the maintenance of the drug-tolerant persister state in cells responding to eribulin
20210 citationsauthor #5
Abstract PS5-12: Preliminary correlative analysis of clinical outcomes withPIK3CAmutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)
20210 citationsauthor #6
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
202161 citationsauthor #8
Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
202141 citationsauthor #11
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
202116 citationsauthor #1
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
20215 citationsauthor #3
Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer
202135 citationsauthor #2
Impact of circulating tumor DNA (ctDNA) detection on survival outcomes of patients (pts) treated with immune-checkpoint inhibitors (ICIs) in early clinical trials.
20210 citationsauthor #13
Abstract PS12-17: Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer)
20214 citationsauthor #7
A phase I/Ib study evaluating GDC-0077 (inavolisib) + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)
20213 citationsauthor #11
Abstract PD1-02: A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) withPIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)
20212 citationsauthor #10
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
202150 citationsauthor #2
Abstract OT-35-01: Solti-1507 A phase ib study of ipatasertib and anti-her2 therapy in her2-positive advanced breast cancer with pik3ca mutation (ipather)
20213 citationsauthor #15
Abstract OT-28-03: VICKI: A Phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC)
20212 citationsauthor #6
Abstract GS3-09: Chances of pregnancy after breast cancer, reproductive and disease outcomes: A systematic review and meta-analysis
20211 citationsauthor #11
Clinical consequences of BRCA2 hypomorphism
202110 citationsauthor #13
ctDNA in Breast Milk for Early Detection of Pregnancy Associated Breast Cancer
20210 citationsauthor #1
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
2021251 citationsauthor #9
Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy
20211 citationsauthor #1
Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.
202119 citationsauthor #11
Clinical consequences of BRCA2 hypomorphism
20210 citationsauthor #13
Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens
20215 citationsauthor #3
A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.
202128 citationsauthor #4
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
202112 citationsauthor #7
Abstract PS4-47: Multi-country clinical validation of can assist breast in Europe indicates robustness of the test
20210 citationsauthor #6
Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant forHER2-mutant, hormone receptor-positive, metastatic breast cancer
20213 citationsauthor #2
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
202125 citationsauthor #5
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.
20214 citationsauthor #21
Abstract 993: GDF15 is a candidate circulating biomarker of eribulin response in breast cancer
20210 citationsauthor #5
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry
20215 citationsauthor #2
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
202133 citationsauthor #5
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy
202146 citationsauthor #7
Abstract PD13-09: Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial
20212 citationsauthor #1
Abstract OT-28-05: Solti-1718 NEREA trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-Enriched (HER2-E) advanced breast cancer (BC)
20210 citationsauthor #1

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT